About Napo Pharma
Napo Pharma is a company based in San Francisco (United States) founded in 2001 by Lisa Conte was acquired by Jaguar Health in February 2017. Napo Pharma has raised $5.14 million across 17 funding rounds from investors including Jaguar Health and Kingdon Capital Management. Napo Pharma offers products and services including Mytesi® and NP-300.
- Headquarter San Francisco, United States
- Founders Lisa Conte
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Napo India Private Limited
- Date of Incorporation 29 Dec, 2005
- Jurisdiction Navi Mumbai, Maharashtra, India
-
Annual Revenue
-
Net Profit
-$62.41 K (USD)-2.67as on Mar 31, 2015
-
EBITDA
-$61.95 K (USD)-2.98as on Mar 31, 2015
-
Total Equity Funding
$5.14 M (USD)
in 17 rounds
-
Latest Funding Round
$2 M (USD), Post-IPO
Jan 03, 2017
-
Investors
Jaguar Health
& 1 more
-
Employee Count
Employee Count
-
Acquired by
Jaguar Health
(Feb 08, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Napo Pharma
Napo Pharma offers a comprehensive portfolio of products and services, including Mytesi® and NP-300.
Treats chemotherapy-induced overactive bowel and related symptoms.
Targets gastrointestinal disorders through novel mechanisms.
Funding Insights of Napo Pharma
Napo Pharma has successfully raised a total of $5.14M across 17 strategic funding rounds. The most recent funding activity was a Post-IPO round of $2 million completed in January 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 17
- Last Round Post-IPO — $2.0M
-
First Round
First Round
(01 Sep 2002)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2017 | Amount | Post-IPO - Napo Pharma | Valuation |
investors |
|
| Jun, 2014 | Amount | Post-IPO - Napo Pharma | Valuation |
investors |
|
| Oct, 2011 | Amount | Post-IPO - Napo Pharma | Valuation |
investors |
|
Investors in Napo Pharma
Napo Pharma has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Jaguar Health and Kingdon Capital Management.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Provides alternative investment management services as a SEC-regulated advisory firm.
|
Founded Year | Domain | Location | |
|
Novel gastrointestinal products for humans and animals are developed sustainably.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Napo Pharma
Financial Statements - Napo Pharma
Napo Pharma Comparisons
Competitors of Napo Pharma
Latest news on Napo Pharma
Frequently Asked Questions about Napo Pharma
Napo Pharma was founded in 2001 and raised its 1st funding round 1 year after it was founded.
Napo Pharma is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Lisa Conte is the current CEO of Napo Pharma. They have also founded this company.
Napo Pharma is a funded company, having raised a total of $5.14M across 17 funding rounds to date. The company's 1st funding round was a Post-IPO of $3.09M, raised on Sep 01, 2002.
Napo Pharmaceuticals was founded in 2001 in San Francisco, United States, where small molecule therapeutics are developed and commercialized for international markets. Emphasis is placed on treatments for diarrheal diseases. Crofelemer has been approved for diarrhea associated with HIVAIDS and licensed to Glenmark and Salix Pharma. Pipeline candidates target insulin-resistant diseases, diarrhea-predominant IBS, acute infectious diarrhea, and pediatric diarrhea.
Napo Pharma offers Mytesi® and NP-300.
Napo Pharma has 2 investors. Key investors include Jaguar Health, and Kingdon Capital Management.